Hovione
Dina M. Silva is an accomplished scientist with extensive experience in various research and development roles. Currently serving as a Senior Scientist at Hovione since September 2022, Dina also holds the position of Lead Scientist at Ab Initio Pharma since 2021. Previously, Dina worked as a Postdoctoral Researcher at the Woolcock Institute of Medical Research from 2018 to 2021 and as a Researcher at the University of Wollongong from 2017 to 2018. Additionally, Dina was the R&D Manager at Biosckin Molecular & Cell Therapies S.A. from 2014 to 2016.
This person is not in any offices
Hovione
2 followers
Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione´s culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.